Zu Post #4644
Meine Empfehlung
splashurl.com/phvn2rf
Meine Empfehlung
splashurl.com/phvn2rf
Neuester,
zuletzt geles. Beitrag
Antworten | Börsenforum Übersicht
Zurück
Weiter
... 185 186 188 189 ...
Antworten | Börsenforum Übersicht
Zurück
Weiter ... 185 186 188 189 ...
Ariad Pharma on the Top
Beiträge: 9.312
Zugriffe: 1.226.468 / Heute: 750
Zugriffe: 1.226.468 / Heute: 750
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI Japan UCITS ETF 1D
Perf. 12M: +155,87%
Xtrackers MSCI Pakistan Swap UCITS ETF 1C
Perf. 12M: +68,36%
Xtrackers Artificial Intelligence and Big Data UCITS ETF 1C
Perf. 12M: +57,05%
Xtrackers S&P 500 2x Leveraged Daily Swap UCITS ETF 1C
Perf. 12M: +53,56%
Xtrackers MSCI USA Communication Services UCITS ETF 1D
Perf. 12M: +51,49%
ich schau mal.
Da ich ja eh progger bin, bastle ich mir grad nen kleines Produkt, dass mit erst mal 3x am Tag die Daten vom HealtCare Sektor runter lutscht, so dass ich mal nen Überblick habe was es so alles da drüben gibt. Sind ja schon einige Raketen an einem vorbei gegangen :(
Da ich ja eh progger bin, bastle ich mir grad nen kleines Produkt, dass mit erst mal 3x am Tag die Daten vom HealtCare Sektor runter lutscht, so dass ich mal nen Überblick habe was es so alles da drüben gibt. Sind ja schon einige Raketen an einem vorbei gegangen :(
@garak
Wo und womit ziehst du dir die Daten? Kannst du das per Script irgendwo online stellen? Würde mich sehr interessieren!!
Wo und womit ziehst du dir die Daten? Kannst du das per Script irgendwo online stellen? Würde mich sehr interessieren!!
42.140.907 Shares Short
splashurl.com/pvcfvus
splashurl.com/pvcfvus
aktuell zieh ich mir die reinen NASDAQ Daten über
www.nasdaq.com/screening/...h+Care&pagesize=200&page=3
bzw.
www.nasdaq.com/screening/...200&page=3&render=download
Bin grad dabei mir noch die Historischen Daten zu siehen
www.nasdaq.com/symbol/agio/historical
unten download this file ...
so richtig anfreunden kann ich mich aber mit der Version noch nicht, aber bei googlefinance bzw. yahoo oder Tradegate hab ich noch nix gefunden, aber sitze ja auch erst seit 2h dran :)
www.nasdaq.com/screening/...h+Care&pagesize=200&page=3
bzw.
www.nasdaq.com/screening/...200&page=3&render=download
Bin grad dabei mir noch die Historischen Daten zu siehen
www.nasdaq.com/symbol/agio/historical
unten download this file ...
so richtig anfreunden kann ich mich aber mit der Version noch nicht, aber bei googlefinance bzw. yahoo oder Tradegate hab ich noch nix gefunden, aber sitze ja auch erst seit 2h dran :)
.... grad meine Regierung aus dem Schlafzimmer schreit ich solle nun schluss machen ...... na dann uns allen morgen einen Bullischen Tag
ARIAD Pharmaceuticals, Inc. Battling Back
By Brian Orelli | More Articles | Save For Later
February 26, 2014 | Comments (0)
After getting its drug pulled off the market for a few months, the relaunch of ARIAD Pharmaceuticals' (NASDAQ: ARIA ) Iclusig is going about as good as could be expected.
When Iclusig was pulled off the market, there were 640 leukemia patients on the drug. During the five weeks since it's been back on the market, 180 patients have come off the temporary free drug program that was available while the drug was off the market. ARIAD thinks there's another 50 or so patients that will transition to the commercial product once they finish their free supply. And more than 100 additional prescriptions for patients not in the free program have been written.
Source: ARIAD Pharmaceuticals.
Going from those 330 patients to get back to 640 and beyond will be an uphill battle. Iclusig has safety issues that will likely make it a treatment of last resort for most leukemia patients. Instead of competing directly with Novartis' (NYSE: NVS ) Gleevec and Bristol-Myers Squibb's (NYSE: BMY ) Sprycel, ARIAD will be getting Novartis' and Bristol-Myers' castoffs that either fail their drugs or can't take them. Because they're likely to be sicker, the patients will stay on Iclusig for a shorter time, reducing the commercial opportunity.
Management didn't give sales guidance for Iclusig, but we can do some math to figure out what they're expecting based on the guidance they did give.
R&D expenses of $140 million to $150 million
SG&A expenses of $135 million to $145 million
Noncash expenses included in the two categories above of $35 million to $45 million
Cash used in operations of $155 million to $175 million
To get the expected cash generated by sales of Iclusig, you just add up the other expenses, back out the noncash expenses, and subtract the amount of cash Ariad plans to use. At the midpoint of the estimate ranges, you get around $80 million.
That's not exactly the blockbuster potential that investors thought Iclusig had a few months ago. And it's a little scary that Ariad could stop all of its research and development and the company still wouldn't be cash flow positive this year.
You've got to spend money to make money
Iclusig is approved in the EU, but it takes awhile to get reimbursement set up in each individual country. In the fourth quarter, sales came from just five of the 15 E.U. countries ARIAD plans to enter in 2014. Presumably the SG&A expenses as a percent of revenue will decrease substantially as those additional EU countries and Switzerland get up and running.
On the R&D front, about 75% of the expenses are for trials on Iclusig. ARIAD is running a trial to test lower concentrations of the drug, which might be efficacious enough but have reduced side effects. It's also running trials in solid tumors where side effects might be less of an issue because patients might not have to stay on the drug as long.
ARIAD's other drug, AP26113, will start a pivotal clinical trial testing the drug in lung cancer patients resistant to Pfizer's (NYSE: PFE ) Xalkori by the end of the first quarter. Like Iclusig, testing it on late-stage patients will reduce the market opportunity, but will increase the likelihood of approval since it can be tested against placebo and not directly against Pfizer's drug.
ARIAD can always go back and do a head-to-head comparison with AP26113 and Xalkori. Of course, that was the plan for Iclusig against Novartis' Gleevec, and that didn't exactly turn out as planned.
Profiting from an idea before it hits the mainstream
Let's face it, every investor wants to get in on revolutionary ideas before they hit it big. Like buying PC-maker Dell in the late 1980's, before the consumer computing boom. Or purchasing stock in e-commerce pioneer Amazon.com in late 1990's, when they were nothing more than an upstart online bookstore. The problem is, most investors don't understand the key to investing in hyper-growth markets. The real trick is to find a small-cap "pure-play", and then watch as it grows in EXPLOSIVE lock-step with it's industry. Our expert team of equity analysts has identified 1 stock that's poised to produce rocket-ship returns with the next $14.4 TRILLION industry. Click here to get the full story in this eye-opening report.
By Brian Orelli | More Articles | Save For Later
February 26, 2014 | Comments (0)
After getting its drug pulled off the market for a few months, the relaunch of ARIAD Pharmaceuticals' (NASDAQ: ARIA ) Iclusig is going about as good as could be expected.
When Iclusig was pulled off the market, there were 640 leukemia patients on the drug. During the five weeks since it's been back on the market, 180 patients have come off the temporary free drug program that was available while the drug was off the market. ARIAD thinks there's another 50 or so patients that will transition to the commercial product once they finish their free supply. And more than 100 additional prescriptions for patients not in the free program have been written.
Source: ARIAD Pharmaceuticals.
Going from those 330 patients to get back to 640 and beyond will be an uphill battle. Iclusig has safety issues that will likely make it a treatment of last resort for most leukemia patients. Instead of competing directly with Novartis' (NYSE: NVS ) Gleevec and Bristol-Myers Squibb's (NYSE: BMY ) Sprycel, ARIAD will be getting Novartis' and Bristol-Myers' castoffs that either fail their drugs or can't take them. Because they're likely to be sicker, the patients will stay on Iclusig for a shorter time, reducing the commercial opportunity.
Management didn't give sales guidance for Iclusig, but we can do some math to figure out what they're expecting based on the guidance they did give.
R&D expenses of $140 million to $150 million
SG&A expenses of $135 million to $145 million
Noncash expenses included in the two categories above of $35 million to $45 million
Cash used in operations of $155 million to $175 million
To get the expected cash generated by sales of Iclusig, you just add up the other expenses, back out the noncash expenses, and subtract the amount of cash Ariad plans to use. At the midpoint of the estimate ranges, you get around $80 million.
That's not exactly the blockbuster potential that investors thought Iclusig had a few months ago. And it's a little scary that Ariad could stop all of its research and development and the company still wouldn't be cash flow positive this year.
You've got to spend money to make money
Iclusig is approved in the EU, but it takes awhile to get reimbursement set up in each individual country. In the fourth quarter, sales came from just five of the 15 E.U. countries ARIAD plans to enter in 2014. Presumably the SG&A expenses as a percent of revenue will decrease substantially as those additional EU countries and Switzerland get up and running.
On the R&D front, about 75% of the expenses are for trials on Iclusig. ARIAD is running a trial to test lower concentrations of the drug, which might be efficacious enough but have reduced side effects. It's also running trials in solid tumors where side effects might be less of an issue because patients might not have to stay on the drug as long.
ARIAD's other drug, AP26113, will start a pivotal clinical trial testing the drug in lung cancer patients resistant to Pfizer's (NYSE: PFE ) Xalkori by the end of the first quarter. Like Iclusig, testing it on late-stage patients will reduce the market opportunity, but will increase the likelihood of approval since it can be tested against placebo and not directly against Pfizer's drug.
ARIAD can always go back and do a head-to-head comparison with AP26113 and Xalkori. Of course, that was the plan for Iclusig against Novartis' Gleevec, and that didn't exactly turn out as planned.
Profiting from an idea before it hits the mainstream
Let's face it, every investor wants to get in on revolutionary ideas before they hit it big. Like buying PC-maker Dell in the late 1980's, before the consumer computing boom. Or purchasing stock in e-commerce pioneer Amazon.com in late 1990's, when they were nothing more than an upstart online bookstore. The problem is, most investors don't understand the key to investing in hyper-growth markets. The real trick is to find a small-cap "pure-play", and then watch as it grows in EXPLOSIVE lock-step with it's industry. Our expert team of equity analysts has identified 1 stock that's poised to produce rocket-ship returns with the next $14.4 TRILLION industry. Click here to get the full story in this eye-opening report.
Posting #4658 steht unter Posting #2155 im Thread Ariad Pharma Neu in "Deutsch"
Gelöschter Beitrag.
Einblenden
»
#4660 
Die Day Trader haben scheinbar nicht mehr so viel Chancen, 2-stellige Gewinne innerhalb von kurzer Zeit zu generieren.
sind wir aktuelle bei
$8.47 -0.08$ -0.94%
na schauen wir mal was der heutige Tag bringt
$8.47 -0.08$ -0.94%
na schauen wir mal was der heutige Tag bringt
aber will erst selber rein ;-)
gerne wissen Masterbroker. Kannst mir ja auch ne BM senden. Du scheinst das gewisse Etwas zu haben.
Ne ich schreibe es gleich hier rein dann haben alle die selbe chance ;-) keine Handlungsempfehlung nur mein Persönliche meinung um es hier rechtlich mal was gerade zu biegen ;-)
fast alles rot egal welche branche. Uns wird es nicht besser gehen...
am besten die Maschine ausmachen und joggen gehen....
baut spannung macht und macht das Köpfchen frei
baut spannung macht und macht das Köpfchen frei
keine Ahnung aber Ariad macht echt keinen Spaß,
mal geht's einen Schritt hoch dann zwei runter.
immer um die 6€
Guck mir das noch eine Woche an dann schmeiß ich das Tuch
mal geht's einen Schritt hoch dann zwei runter.
immer um die 6€
Guck mir das noch eine Woche an dann schmeiß ich das Tuch
schaut euch mal ne Xoma an, hab sie seit zwei Wochen und macht Spaß
KEINE EMPFEHLUNG MEINE MEINUNG
KEINE EMPFEHLUNG MEINE MEINUNG
|
Neueste Beiträge aus dem ARIAD Pharmaceuticals, Inc. Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 58 | ARIAD Pharmaceuticals Inc. | JoWu81 | Card60 | 25.04.21 01:33 | ||
3 | 46 | Ariad Pharmaceuticals Inc. A real hot stock! | FernandeZ | FernandeZ | 25.04.21 00:53 | |
| 18 | 4.875 | Ariad Pharmaceuticals - der letzte Thread | steven-bln | vstrecker | 25.04.21 00:38 | |
| 23 | 3.206 | Ariad Pharmaceuticals-Neu | Heron | Heron | 04.12.18 18:56 | |
| 36 | 9.311 | Ariad Pharma on the Top | MasterbrokerUSA | MasterbrokerUSA | 26.09.16 18:45 |
